-
公开(公告)号:EP4433467A1
公开(公告)日:2024-09-25
申请号:EP22818305.9
申请日:2022-11-15
IPC分类号: C07D401/04 , C07D403/04 , C07D409/04 , C07D491/056 , A01N43/58
CPC分类号: C07D401/04 , C07D409/04 , C07D403/04 , C07D491/056 , A01N43/58 , A01P13/02
-
公开(公告)号:EP4429663A1
公开(公告)日:2024-09-18
申请号:EP22893790.0
申请日:2022-11-09
IPC分类号: A61K31/4725 , A61K31/472 , A61K31/502 , C07D217/22 , C07D237/30 , C07D237/32
CPC分类号: C07D237/32 , C07D491/056 , C07D401/10 , C07D403/10 , C07D405/14 , C07D401/14 , C07D401/04 , C07D471/04 , C07D405/12 , C07D513/04 , C07D217/24
-
公开(公告)号:EP4412606A1
公开(公告)日:2024-08-14
申请号:EP22879536.5
申请日:2022-10-07
发明人: BOEZIO, Alessandro , TAYLOR, Alexander M. , ZHANG, Junyi , SHORTSLEEVES, Kelley C. , PIERCE, Levi Charles Thomas , MCLEAN, Thomas H. , KAPLAN, Anna , MADEC, Amaël , HUDSON, Brandi M. , MA, Jun , PAN, Yue , MAERTENS, Gaetan , OUTIN, Johanne
IPC分类号: A61K31/33 , A61K31/435 , A61K31/4545 , A61K31/505
CPC分类号: C07D471/04 , C07D311/22 , C07D405/12 , C07D405/04 , C07D405/14 , C07D239/95 , C07D405/06 , C07D417/12 , C07D487/04 , C07D519/00 , C07D401/14 , C07D401/12 , C07D401/04 , C07D491/056 , C07D403/04 , C07D239/88 , C07D239/91
-
公开(公告)号:EP3757090B1
公开(公告)日:2024-06-12
申请号:EP20177336.3
申请日:2009-11-10
IPC分类号: C07D317/46 , A61K31/713 , A61P33/00 , A61K9/127 , A61K31/7088 , A61P37/04 , C07D203/10 , C07D317/28 , C07D317/44 , C07D405/12 , C07D317/72 , C07D491/056 , A61K39/00 , A61P35/00 , C07D319/06 , C07D491/113 , C12N15/11
CPC分类号: A61K39/00 , C12N15/111 , A61K9/1272 , A61K31/713 , C07D319/06 , C07D317/28 , C07D203/10 , A61K31/7088 , C07D317/44 , C07D317/46 , C07D317/72 , C07D405/12 , C07D491/056 , C07D491/113 , A61P33/00 , A61P35/00 , A61P37/04 , Y02A50/30
-
公开(公告)号:EP3842425B1
公开(公告)日:2024-05-22
申请号:EP19851019.0
申请日:2019-08-23
IPC分类号: C07D401/14 , C07D491/056 , A61K31/4709 , A61K31/501 , A61K31/506 , A61P35/00 , A61P15/00 , A61P9/00 , A61P17/06 , A61P27/02 , A61P19/02 , A61P19/10 , A61P29/00 , A61P13/12 , A61K45/06 , A61P35/02 , A61P35/04 , C07D213/80 , C07D237/24
CPC分类号: A61K31/4709 , A61K31/501 , A61K31/506 , A61P35/00 , A61P35/02 , A61P35/04 , C07D401/14 , C07D491/056 , A61P29/00 , A61P15/00 , A61P19/02 , A61P19/10 , A61P9/00 , A61P13/12 , A61P27/02 , A61P17/06 , C07D213/80 , C07D237/24 , A61K45/06
-
公开(公告)号:EP3687538B1
公开(公告)日:2024-04-17
申请号:EP18874508.7
申请日:2018-10-30
IPC分类号: A61K31/44 , A61P3/06 , A61P9/10 , C07D213/81
CPC分类号: A61K31/44 , C07D213/79 , C07D213/81 , C07D213/82 , C07D491/056 , A61P3/06 , A61P9/10 , A61K31/443
-
公开(公告)号:EP2836487B1
公开(公告)日:2018-10-31
申请号:EP13717647.5
申请日:2013-04-03
发明人: CASTRO, Alfredo, C. , CHAN, Katrina , EVANS, Catherine, A. , JANARDANANNAIR, Somarajannair , LESCARBEAU, Andre , LI, Liansheng , LIU, Tao , LIU, Yi , REN, Pingda , SNYDER, Daniel, A. , TREMBLAY, Martin, R.
IPC分类号: C07D401/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D217/24 , C07D403/14 , C07D413/12 , C07D471/04 , C07D495/04 , A61K31/517 , A61P35/00 , A61P37/00
CPC分类号: C07D519/00 , A61K31/519 , C07D217/24 , C07D217/26 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/056 , C07D495/04 , C07D513/04 , Y02A50/414
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
-
8.
公开(公告)号:EP3283462A1
公开(公告)日:2018-02-21
申请号:EP16718179.1
申请日:2016-04-15
申请人: Araxes Pharma LLC
发明人: LI, Liansheng , FENG, Jun , LONG, Yun, Oliver , LIU, Yuan , WU, Tao , REN, Pingda , LIU, Yi
IPC分类号: C07D219/10 , C07D219/12 , C07D471/04 , C07D491/056 , C07D498/04 , C07D513/04 , A61K31/4375 , A61P35/00
CPC分类号: C07D471/04 , C07D219/10 , C07D219/12 , C07D491/056 , C07D498/04 , C07D513/04
摘要: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):(I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A is a heterocyclic or heteroaryl ring, and R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, A, G1, G2, L1, L2, m1, m2, and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
-
9.BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF 有权
标题翻译: 桥环化合物作为丙型肝炎病毒(HCV)抑制剂及其药物应用公开(公告)号:EP2880030B1
公开(公告)日:2018-01-10
申请号:EP13824843.0
申请日:2013-08-05
发明人: ZHANG, Yingjun , ZHANG, Jiancun , XIE, Hongming , REN, Qingyun , TAN, Yumei , LUO, Huichao
IPC分类号: C07D403/14 , C07D401/14 , A61K31/4178 , A61K31/4025 , A61P31/12 , C07D405/14
CPC分类号: C07D403/14 , A61K31/4178 , A61K31/4184 , A61K31/427 , A61K31/439 , A61K31/4545 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D453/06 , C07D471/08 , C07D491/056 , C07D491/113 , C07D493/08 , C07D519/00
摘要: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.
-
公开(公告)号:EP3116858A4
公开(公告)日:2017-11-22
申请号:EP15760744
申请日:2015-03-16
申请人: RAQUALIA PHARMA INC
发明人: SHISHIDO YUJI , OHMI MASASHI , ANDO KAZUO
IPC分类号: C07D235/02 , A61K31/41 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/427 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/501 , A61K31/506 , A61P1/00 , A61P9/10 , A61P11/00 , A61P13/02
CPC分类号: C07D491/056 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/423 , A61K31/427 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/538 , C07D235/02 , C07D235/06 , C07D263/52 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/10 , C07D409/14 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048
摘要: The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.
-
-
-
-
-
-
-
-
-